Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Lisa M. Neff, Michelle Weil, Alan Cole, Thomas R. Hedges, William Shucart, Donald Lawrence, Jay Jiguang Zhu, Arthur S. Tischler, Ronald M. Lechan*

*Corresponding author for this work

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalPituitary
Volume10
Issue number1
DOIs
StatePublished - Mar 1 2007

Keywords

  • Dopamine agonist resistance
  • Prolactinoma
  • Temozolomide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists'. Together they form a unique fingerprint.

  • Cite this

    Neff, L. M., Weil, M., Cole, A., Hedges, T. R., Shucart, W., Lawrence, D., Zhu, J. J., Tischler, A. S., & Lechan, R. M. (2007). Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary, 10(1), 81-86. https://doi.org/10.1007/s11102-007-0014-1